Benzinga | Mar 26, 2021 08:57AM EDT

BTIG Maintains Buy on BioAtla, Raises Price Target to $87

BTIG analyst Thomas Shrader maintains BioAtla (NASDAQ:BCAB) with a Buy and raises the price target from $47 to $87.